Association between Isometric and Allometric Height-Indexed Left Atrial Size and Atrial Fibrillation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Background: Height-based indexations for the evaluation of left atrial (LA) volumes have been proposed as an alternative method to account for body stature when body composition is abnormal. The aim of this study was to derive reference values for these indexation methods and to examine their association with atrial fibrillation (AF). Methods: A healthy population was randomly split into derivation and validation cohorts (n = 493 each). The derivation cohort was used to derive reference values for iso- and allometric height-indexed LA volumes. Echocardiography included measurement of maximal LA volume (LAVmax) and minimal LA volume (LAVmin). Associations between these measures and AF were investigated in the validation cohort. Cox proportional-hazards regression was performed, adjusting for CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology Atrial Fibrillation) risk score. Results: From 986 healthy subjects, allometric height-indexed exponents were determined to 1.72 and 1.56 for LAVmax and LAVmin, respectively. Upper reference values were determined to be LAVmax > 22.1 mL/m1.72 and LAVmin > 12.7 mL/m1.56. In the validation cohort, 41 patients (8%) developed AF during follow-up (median, 14.7 years). In unadjusted analyses, both isometric and allometric indexed LAVmax were associated with AF (hazard ratio, 1.07 [95% CI, 1.03-1.11; P <.001] and 1.11 [95% CI, 1.05-1.18; P <.001] per 1 mL/m and 1 mL/m1.72 increase, respectively) with equal C statistics of 0.63. Height-indexed LAVmin was also associated with AF, with higher C statistics than for LAVmax. All findings were consistent after multivariable adjustment. LAVmax > 22.1 mL/m1.72 posed an increased risk for AF (hazard ratio, 4.65; 95% CI, 1.83-11.86), but LAVmin > 12.7 mL/m1.56 carried a higher risk (hazard ratio, 6.33; 95% CI, 2.66-15.07). Conclusions: Both isometric and allometric height-indexed LA volumes are associated with AF in the general population. LAVmin is more strongly associated with AF than LAVmax regardless of indexation.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of the American Society of Echocardiography |
| Vol/bind | 35 |
| Udgave nummer | 2 |
| Sider (fra-til) | 141-150.e4 |
| ISSN | 0894-7317 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
The Copenhagen City Heart Study was funded by the Danish Heart Foundation, and the echocardiographic substudy was funded by the Lundbeck Foundation, Denmark. Dr Olsen was funded by research grants from the Danish Heart Foundation (18-R125-A8534-22083), Fru Asta Florida Boldings Mindelegat, Kong Christian X Fond, and Herlev & Gentofte Hospital's Research Foundation. Dr Biering-S?rensen was supported by Fondb?rsvekselerer Henry Hansen og Hustrus Hovedlegat, the Lundbeck Foundation, and the Novo Nordisk Foundation, Denmark. The sponsors had no role in the study concept, design, or conduct or the interpretation of the data. Dr Biering-S?rensen is a steering committee member for the Amgen-financed GALACTIC-HF trial and the Boston Scientific?financed LUX-Dx TRENDS trial; is an advisory board member for Sanofi Pasteur and Amgen; has received speaking honoraria from Novartis and Sanofi Pasteur; and has received research grants from GE Healthcare and Sanofi Pasteur. These companies had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.
Funding Information:
The Copenhagen City Heart Study was funded by the Danish Heart Foundation , and the echocardiographic substudy was funded by the Lundbeck Foundation, Denmark. Dr Olsen was funded by research grants from the Danish Heart Foundation ( 18-R125-A8534-22083 ), Fru Asta Florida Boldings Mindelegat , Kong Christian X Fond , and Herlev & Gentofte Hospital’s Research Foundation . Dr Biering-Sørensen was supported by Fondbørsvekselerer Henry Hansen og Hustrus Hovedlegat, the Lundbeck Foundation , and the Novo Nordisk Foundation, Denmark. The sponsors had no role in the study concept, design, or conduct or the interpretation of the data. Dr Biering-Sørensen is a steering committee member for the Amgen-financed GALACTIC-HF trial and the Boston Scientific–financed LUX-Dx TRENDS trial; is an advisory board member for Sanofi Pasteur and Amgen; has received speaking honoraria from Novartis and Sanofi Pasteur; and has received research grants from GE Healthcare and Sanofi Pasteur. These companies had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.
Publisher Copyright:
© 2021 American Society of Echocardiography
ID: 288190669